Scholarlink

<p>We determine nemolizumab’s safety and efficacy in moderate/severe atopic dermatitis (AD). Embase, Cochrane, PubMed, and Web of Science were searched up to 15 January 2025 for randomized controlled trials (RCTs) on nemolizumab’s efficacy and safety in moderate/severe AD. This meta-analysis comprised 6 RCTs (including 13 control groups) and found that nemolizumab significantly improved pruritus numerical rating scale (RR = 2.41; 95% CI: 2.02–2.88), investigator’s global assessment (IGA) (RR = 1.49; 95% CI: 1.28–1.73), and eczema area and severity index 75 (EASI-75) responses (RR = 1.47; 95% CI: 1.29–1.67). Nemolizumab improved pruritus visual-analogue scale (VAS) [(SMD: -0.84; 95% CI: -1.09, -0.60), patient-oriented eczema measure [(SMD: -0.54; 95% CI: -0.70, -0.37), dermatology life quality index [(SMD: -0.26; 95% CI: -0.37, -0.16), and children’s dermatology life quality index [(SMD: -0.41; 95% CI: -0.72, -0.10) (all <i>P</i> &lt; 0.00001). As a novel treatment modality, nemolizumab effectively relieves pruritus, clears skin lesions, and improves EASI and IGA scores without an increase in serious adverse effects in moderate/severe AD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of nemolizumab for moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月4日

查看全文
  • Ling Li,
  • Jiajun Yu,
  • Dan Huang,
  • Huiwen Zhou,
  • Nian Mo,
  • Wenting Hu,
  • Fang Qian

摘要

We determine nemolizumab’s safety and efficacy in moderate/severe atopic dermatitis (AD). Embase, Cochrane, PubMed, and Web of Science were searched up to 15 January 2025 for randomized controlled trials (RCTs) on nemolizumab’s efficacy and safety in moderate/severe AD. This meta-analysis comprised 6 RCTs (including 13 control groups) and found that nemolizumab significantly improved pruritus numerical rating scale (RR = 2.41; 95% CI: 2.02–2.88), investigator’s global assessment (IGA) (RR = 1.49; 95% CI: 1.28–1.73), and eczema area and severity index 75 (EASI-75) responses (RR = 1.47; 95% CI: 1.29–1.67). Nemolizumab improved pruritus visual-analogue scale (VAS) [(SMD: -0.84; 95% CI: -1.09, -0.60), patient-oriented eczema measure [(SMD: -0.54; 95% CI: -0.70, -0.37), dermatology life quality index [(SMD: -0.26; 95% CI: -0.37, -0.16), and children’s dermatology life quality index [(SMD: -0.41; 95% CI: -0.72, -0.10) (all P < 0.00001). As a novel treatment modality, nemolizumab effectively relieves pruritus, clears skin lesions, and improves EASI and IGA scores without an increase in serious adverse effects in moderate/severe AD.